We are live on !
Find out more
Syquant Capital Portfolio holdings
AUM
$453M
Turnover
61.97%
1-Year Est. Return
6.35%
This Fund
S&P 500
This Quarter Est. Return
+15.97%
1 Year Est. Return
+6.35%
3 Year Est. Return
+159.76%
5 Year Est. Return
+344.81%
10 Year Est. Return
–
AUM
$302M
AUM Growth
+$161M
(+114%)
Cap. Flow
+$138M
Cap. Flow % of AUM
Cap. Flow %
45.6%
Top 10 Holdings %
Top 10 Hldgs %
98.44%
Holding
25
New
10
Increased
2
Reduced
–
Closed
11
Avg Time Held
0.1
years
Top 10 Avg Time Held
0.1
years
Top 20 Avg Time Held
0.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Blueprint Medicines
BPMC
|
+$83.7M |
| 2 |
Kellanova
K
|
+$51.7M |
| 3 |
Triumph Group
TGI
|
+$14.5M |
| 4 |
Walgreens Boots Alliance
WBA
|
+$14.3M |
| 5 |
Dun & Bradstreet
DNB
|
+$11.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intra-Cellular Therapies
ITCI
|
+$35.1M |
| 2 |
Beacon Roofing Supply
BECN
|
+$18.5M |
| 3 |
Despegar.com
DESP
|
+$8.41M |
| 4 |
Playa Hotels & Resorts
PLYA
|
+$4.1M |
| 5 |
H&E Equipment Services
HEES
|
+$2.65M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.44% |
| 2 | Consumer Staples | 30.16% |
| 3 | Financials | 11.77% |
| 4 | Industrials | 4.85% |
| 5 | Technology | 4.01% |
Similar funds
RS
Syquant Capital's Q2 2025 Portfolio in Review
As of Q2 2025, Syquant Capital held 25 positions worth $302M, up 114% from $141M the previous quarter. Its ten largest holdings account for 98% of the portfolio.
Syquant Capital deployed $138M of net new capital in Q2 2025, opening 10 new positions and adding to 2 existing holdings. Its largest new stake was Blueprint Medicines: 805,603 shares worth $103M.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 25% a quarter earlier, followed by Consumer Staples and Financials.
On the sell side, the most notable exit was Intra-Cellular Therapies, an estimated $35.1M sold.
- Syquant Capital's largest Q2 2025 buy was Blueprint Medicines: 805,603 shares worth $103M.
- Syquant Capital added most to Kellanova in Q2 2025, an estimated $51.7M increase.
- Syquant Capital fully exited Intra-Cellular Therapies in Q2 2025, selling an estimated $35.1M.
- Syquant Capital's ten largest holdings make up 98% of its $302M portfolio in Q2 2025.
- Syquant Capital opened 10 new positions and closed 11 in Q2 2025.
- Syquant Capital's portfolio value rose 114% quarter-over-quarter to $302M.
Based on Syquant Capital's 13F filing for Q2 2025, filed 15 Jul 2025.